Crenolanib-CP-868596-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemECrenolanibCat. No.: HY-13223CAS No.: 670220-88-9Synonyms: CP-868596分式: CHNO分量: 443.54作靶點(diǎn): PDGFR; FLT3; Autophagy作通路: Protein Tyrosine Kinase/RTK; Autophagy儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性

2、數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 33.33 mg/mL (75.15 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 2.2546 mL 11.2729 mL 22.5459 mL5 mM 0.4509 mL 2.2546 mL 4.5092 mL10 mM 0.2255 mL 1.1273 mL 2.2546 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?，配制前?qǐng)先配制澄清的儲(chǔ)備液，再依次添加助溶劑(為保證

3、實(shí)驗(yàn)結(jié)果的可靠性，體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 3 mg/mL (6.76 mM); Clear solution2. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 3 mg/mL (6.76 mM); Clear solution3. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% cor

4、n oil1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemESolubility: 3 mg/mL (6.76 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Crenolanib有效和選擇性的野型和突變型 III 類受體酪氨酸激酶抑制劑，抑制 FLT3 和 PDGFR/ 的 Kd分別為 0.74 nM，2.1 nM，3.2 nM。IC50 & Target PDGFR PDGFR FLT32.1 nM (Kd) 3.2 nM (Kd) 0.74 nM (Kd)體外研究 Crenolanib has 25-fo

5、ld more affinity for PDGFRA/B compared with KIT, and is approximately 135-fold morepotent than STI571 for inhibiting the PDGFRA D842V mutation. The IC50 for crenolanib for a KIT exon 11deletion mutant kinase is greater than 1,000 versus 8 nM for STI571. Crenolanib has low nanomolar potencyagainst th

6、e V561D + D842V-mutant kinase that is similar to its potency against the isolated D842V mutation.Both STI571 and crenolanib potently inhibit the kinase activity of the fusion oncogene with IC50 values of 1and 21 nM, respectively, and inhibits PDGFRA activation in this cell line with IC50 values of 9

7、3 and 26 nM,respectively 1. HL60/VCR and K562/ABCB1 cells, overexpressing ABCB1, are 6.9- and 3.6-fold resistant tocrenolanib, respectively, in relation to parental HL60 and K562 cells. PSC-833 fully reverses resistance tocrenolanib in both HL60/VCR and K562/ABCB1 cells. Crenolanib (1 nM-10 M) stimu

8、lates ABCB1 ATPaseactivity in a concentration-dependent manner. Crenolanib treatment does not increase the cell surfaceexpression of ABCB1. Crenolanib inhibits 125I-IAAP photocrosslinking of ABCB1 at high concentrations,with 50 % inhibition at 10 M, but has little effect at lower concentrations, bel

9、ow 1 M 2. Crenolanibdecreases NSCLC cell viability, induces apoptosis in NSCLC cells, and inhibits cell migration in NSCLC cells3.體內(nèi)研究 Crenolanib (10 mg/kg and 20 mg/kg) suppresses non-small-cell lung cancer tumor growth in vivo andinduces tumor cell apoptosis, and the dosage of crenolanib applied i

10、s well tolerated by recipient mice 3.PROTOCOLCell Assay 2 Viable cell numbers following drug treatment are measured using the WST-1 assay. Briefly, 1103 cells areseeded in 100 L complete medium per well in 96-well tissue culture plates and incubated with crenolanib (0-10 M) at 37C in 5% CO2 for 96 h

11、. 10 L WST-1 reagent is then added to each well, incubation is continuedfor two additional hours and the color developed is quantified according to the manufacturers instructions.Each experiment is performed in triplicate. IC50 concentrations are calculated by the least square fit ofdoseresponse inh

12、ibition in a non-linear regression model using GraphPad Prism V software.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal A549 cells are injected into the axillary regions of mice (2106 cells/mouse). When the tumor volumesAdministration 3 reached

13、70 mm3, the mice are randomLy allocated to the control group, low-dose crenolanib group (10mg/kg), or high-dose crenolanib group (20 mg/kg) (n=6 per group). The vehicle for crenolanib treatmentconsists of 10% 1-methyl-2-pyrrolidinone and 90% polyethylene glycol 300. The tumor size and mouse body2/3

14、Master of Small Molecules 您邊的抑制劑師www.MedChemEweight are measured every other day for about 2 weeks. The tumor volume is calculated as follows:(mm3)=(widthwidthlength)/2. After treatment, the mice are euthanized using carbon dioxide, and thetumors are harvested and analyzed.MCE has not independently

15、confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Sci Transl Med. 2018 Jul 18;10(450). pii: eaaq1093. Blood. 2018 Jan 25;131(4):426-438. J Med Chem. 2019 Mar 14;62(5):2428-2446. Brit J Haematol. 2019. Jul. Stem Cell Res Ther. 2015 Dec 10;6:243.See more customer validat

16、ions on HYPERLINK / www.MedChemEREFERENCES1. Heinrich MC, et al.Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with STI571-resistant gastrointestinalstromal tumors. Clin Cancer Res, 2012, Jun 27.2. Mathias TJ, et al. The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does notinhibit transport function at pharmacologically relevant concentrations. Invest New Drugs. 2015 Apr;33(2):300-9.3. Wang P, et al. Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor